A target heart rate of 55-60 beats per minute is a goal for propranolol in both primary and secondary prophylaxis of variceal hemorrhage (VH). However, dose adjustments are often needed based on baseline heart rates. This study analyzed the effect of heart rate reduction from baseline with propranolol therapy on VH in patients with cirrhosis. A retrospective study was conducted on cirrhotic patients receiving propranolol for primary and secondary prophylaxis, 2008-2023. Patients were categorized as responders or non-responders based on the achievement of a heart rate reduction of ≥ 25% from baseline. The primary outcome was the incidence of VH. A survival analysis with propensity score-inverse probability treatment weighting was performed to associate heart rate reduction and the outcome. Among the 215 patients treated with propranolol for primary prophylaxis, 72 (33.5%) were responders and 143 (66.5%) non-responders. In secondary prophylaxis, 157 patients were included, with 52 (33.1%) classified as responders and 105 (66.9%) as non-responders. The median Child-Pugh score was 6 (range 5-12) for primary and 7 (range 5-12) for secondary prophylaxis. Responders and non-responders showed a similar incidence of VH in both primary (adjusted hazard ratio (HR) 1.70, 95% CI: 0.82-3.49) and secondary prophylaxis (adjusted HR 1.00, 95% CI: 0.34-2.90). Our analysis did not support achieving a heart rate reduction of ≥ 25% from baseline as a response to propranolol for the primary and secondary prophylaxis of VH in cirrhosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886985 | PMC |
http://dx.doi.org/10.1111/cts.70192 | DOI Listing |
Front Immunol
March 2025
Division of Metabolomics, Proteomics & Imaging facility, Regional Medical Research Centre, Indian Council of Medical Research (ICMR), Dibrugarh, Assam, India.
Background: Although the SARS-CoV-2 and dengue viruses seriously endanger human health, there is presently no vaccine that can stop a person from contracting both viruses at the same time. In this study, four antigens from SARS-CoV-2 and dengue virus were tested for immunogenicity, antigenicity, allergenicity, and toxicity and chosen to predict dominant T- and B-cell epitopes.
Methods: For designing a multi-epitope vaccine, the sequences were retrieved, and using bioinformatics and immunoinformatics, the physicochemical and immunological properties, as well as secondary structures, of the vaccine were predicted and studied.
Biosaf Health
August 2024
National Pathogen Resource Center, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
In recent years, as the infectious diseases caused by pathogens such as novel coronavirus and mpox (formerly called monkeypox) spread globally, the significance of identification, preservation, and sharing of pathogenic resources become prominent. Along with the rapid development of biorepositories, it is imperative to evaluate their operation in a scientific manner. By using the literature review and modified Delphi method, this study develops a benchmarking tool for the comprehensive evaluation of the operation of biorepositories for pathogenic resources.
View Article and Find Full Text PDFBiosaf Health
August 2024
NHC Key Laboratory of Biosafety, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China.
The effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection persist months and years after recovery. We conducted an online survey to assess the health condition of convalescents approximately 5 months following the primary infection of SARS-CoV-2. The study recruited 5,510 individuals who were primary infected, 626 participants who had experienced reinfection, and 521 participants who were without infective history.
View Article and Find Full Text PDFAm J Health Syst Pharm
March 2025
Indiana University Health, Indianapolis, IN, USA.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFObjectives: This study assessed the utility of Cameron's Illness Risk Representation (IRR) framework in understanding how women interpret their breast cancer risk after receiving a clinically derived estimate.
Design: Secondary qualitative analysis of two studies within the BC-Predict trial, using semi-structured telephone interviews with women aged 47-74 who received breast cancer risk estimates via population screening.
Methods: Forty-eight women were informed of their 10-year breast cancer risk (low (<1.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!